Current status of the treatment of Argentine Hemorrhagic Fever

Autochthonous Crimean–Congo Hemorrhagic Fever in Spain

“…Since the disease was first recognized in 1955, annual outbreaks have been notified without interruption, with more than 24.000 cases reported in 1993 (7,(12)(13)(14). The endemo-epidemic area of the disease is located in the humid pampa, the most fertile farm land of Argentina (15).…”

“…However, this treatment is only effective if given during the first 8 day-period after onset of symptoms. In addition plasma therapy entails risk of transfusion-borne diseases and the presentation of a late neurologic syndrome (LNS) that has been occurred in 10% of treated survivors (7,(12)(13)(14).…”

“…There are only few animal and human studies on the clinical effectiveness of ribavirin in the treatment of New World Arenaviridae (7,(12)(13)(14). These limited clinical data indicate a clear benefit of ribavirin treatment, with good tolerability and safety of the drug (7,(12)(13)(14).…”

“…These limited clinical data indicate a clear benefit of ribavirin treatment, with good tolerability and safety of the drug (7,(12)(13)(14).…”

The arenaviruses

“…Human immune plasma must be given to patients within 8 days of onset, and treatment may be complicated by development of a transient late-onset neurologic syndrome. 94,95 Immune therapy may also be effective against Machupo virus infection, but there are too few cases to maintain a reliable source of immune plasma.…”